Pharmafile Logo

News and Press Releases

Ellipses In-Licences First in Class Novel Immuno-Oncology Agent with Potential as a Next Generation Checkpoint Inhibitor

11 February 2025 -- London, UK -- Ellipses Pharma Limited, a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced...

Category: BioManufacturing, Drug Discovery, Other, Pharmaceutical
Posted: February 11, 2025

Ellipses Pharma
enquiries@ellipses.life
10 STRATTON STREET W1J 8LG LONDON

Ellipses Pharma Publishes Data from Ongoing Phase 1/2 Clinical Trial of EP0042

9 December 2024 -- London, UK -- Ellipses Pharma Limited, a global drug development company focused on accelerating the development of new oncology treatments, has published the latest data from...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 9, 2024

Ellipses Pharma
enquiries@ellipses.life
10 STRATTON STREET W1J 8LG LONDON

Ellipses’ next generation selective RET inhibitor EP0031/A400 cleared to start phase 2

Drug has successfully completed US Food and Drug Administration (FDA)’s End of Phase 1 data review 1 May 2024 -- London, UK -- Ellipses Pharma, a global drug development company...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: May 1, 2024

Ellipses Pharma
enquiries@ellipses.life
10 STRATTON STREET W1J 8LG LONDON

Ellipses’ next generation selective RET inhibitor EP0031/A400 granted Fast Track designation by US Food and Drug Administration

Compound is currently undergoing clinical trials as a potential treatment option for patients with RET altered tumours 5 March 2024 -- London, UK -- Ellipses Pharma, a global drug development...

Category: Drug Discovery
Posted: March 5, 2024

Ellipses Pharma
enquiries@ellipses.life
10 STRATTON STREET W1J 8LG LONDON